Your browser doesn't support javascript.
loading
Comparison of strength testing modalities in dysferlinopathy.
Reash, Natalie F; James, Meredith K; Alfano, Lindsay N; Mayhew, Anna G; Jacobs, Marni; Iammarino, Megan A; Holsten, Scott; Sakamoto, Chikako; Tateishi, Takayuki; Yajima, Hiroyuki; Duong, Tina; de Wolf, Brittney; Gee, Richard; Bharucha-Goebel, Diana X; Bravver, Elena; Mori-Yoshimura, Madoka; Bushby, Kate; Rufibach, Laura E; Straub, Volker; Lowes, Linda P.
Afiliação
  • Reash NF; The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
  • James MK; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Alfano LN; The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
  • Mayhew AG; The John Walton Muscular Dystrophy Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Jacobs M; Center for Translational Science, Division of Biostatistics and Study Methodology, Children's National Health System, Washington, DC.
  • Iammarino MA; Pediatrics, Epidemiology and Biostatistics, George Washington University, Washington, DC.
  • Holsten S; The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio.
  • Sakamoto C; Neuroscience Institute, Carolinas Neuromuscular/ALS-MDA Center, Carolinas HealthCare System, Charlotte, North Carolina.
  • Tateishi T; Department of Physical Rehabilitation, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Yajima H; Department of Physical Rehabilitation, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • Duong T; Department of Physical Rehabilitation, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
  • de Wolf B; Cooperative International Neuromuscular Research Group, Children's National Health System, Washington, DC.
  • Gee R; Lucile Salter Packard Children's Hospital at Stanford, Neurology, Palo Alto, California.
  • Bharucha-Goebel DX; Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California.
  • Bravver E; Cooperative International Neuromuscular Research Group, Children's National Health System, Washington, DC.
  • Mori-Yoshimura M; Lucile Salter Packard Children's Hospital at Stanford, Neurology, Palo Alto, California.
  • Bushby K; Department of Neurology Children's National Health System, Washington, DC.
  • Rufibach LE; National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland.
  • Straub V; Neuroscience Institute, Carolinas Neuromuscular/ALS-MDA Center, Carolinas HealthCare System, Charlotte, North Carolina.
  • Lowes LP; Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan.
Muscle Nerve ; 66(2): 159-166, 2022 08.
Article em En | MEDLINE | ID: mdl-35506767
ABSTRACT
INTRODUCTION/

AIMS:

Dysferlinopathy demonstrates heterogeneity in muscle weakness between patients, which can progress at different rates over time. Changing muscle strength due to disease progression or from an investigational product is associated with changing functional ability. The purpose of this study was to compare three methods of strength testing used in the Clinical Outcome Study (COS) for dysferlinopathy to understand which method and which muscle groups were most sensitive to change over time.

METHODS:

Patients were evaluated at each study visit using functional scales, manual muscle testing, and handheld dynamometry (HHD) at all 15 sites. A fixed-frame system (Fixed) was used at a subset of seven sites. Screening and baseline visits were evaluated for reliability. Data over a 1-year period were analyzed to determine sensitivity to change among strength modalities and individual muscle groups.

RESULTS:

HHD and Fixed captured significant change across 1 year in summed muscle strength score of four muscle groups (P < .01). Strength summed scores were significantly correlated with functional scales (rho = 0.68-0.92, P < .001). Individual muscle groups, however, showed high levels of variability between visits.

DISCUSSION:

Although both HHD and Fixed demonstrate change over 12 months, HHD is a less expensive option that provides data on a continuous scale and may be easier to implement. Due to variability in strength measures, researchers should carefully consider use of strength testing as an outcome and may wish to select functional measures with less variability as clinical trial endpoints.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular do Cíngulo dos Membros / Força Muscular Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Distrofia Muscular do Cíngulo dos Membros / Força Muscular Tipo de estudo: Diagnostic_studies / Guideline Limite: Humans Idioma: En Revista: Muscle Nerve Ano de publicação: 2022 Tipo de documento: Article